Health
Russia’s COVID-19 vaccine shows over 91% efficacy in phase 3 trial: Lancet study – The Tribune India
Findings based on analysis of data from nearly 20,000 participants; Sputnik V is a two-part vaccine that includes two adenovirus vectors
Moscow, February 2
Russia’s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday.
The findings are based on analysis of data from nearly 20,000 participants – three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo.
Serious adverse events or those requiring hospital…
-
Noosa News19 hours agoTwo teenagers and two adults rushed to hospital in life-threatening conditions after shocking Lawnton house fire
-
Noosa News21 hours agoA secret scheme and plans to expel former leaders — here’s what we’ve heard from Queensland’s inquiry into the CFMEU
-
Noosa News20 hours agoFatal traffic crash, Noosa – Sunshine Coast
-
Business20 hours agoTop brokers name 3 ASX shares to buy next week 23 November 2025